Standard treatment for glioblastoma multiforme and other brain tumors consists of surgical resection followed by combined radio-/chemotherapy. However, radiation resistance of tumor cells limits the success of this treatment, and the tumors invariably recur. Therefore, the selective inhibition of molecular mediators of radiation resistance may provide therapeutic benefit to the patient. One of these targets is the Rad51 protein, which is a key component of the homologous recombinational repair of DNA double-strand breaks. Here, we investigated whether post-transcriptional silencing of Rad51 by herpes simplex virus-type 1 (HSV-1) amplicon vectormediated short interfering RNA expression can enhance the antitumor effect of radiation therapy. We demonstrate that these vectors specifically and efficiently inhibited the radiationinduced recruitment of Rad51 into nuclear foci in human glioma cells. The combination of vector-mediated silencing of Rad51 expression and treatment with ionizing radiation resulted in a pronounced reduction of the survival of human glioma cells in culture. In athymyc mice, a single intratumoral injection of Rad51-specific HSV-1 amplicon vector followed by a single radiation treatment resulted in a significant decrease in tumor size. In control animals, including mice that received an intratumoral injection of Rad51-specific amplicon vector but no radiation treatment, the tumor sizes increased.
Introduction
Glioblastoma multiforme is the most common and most aggressive brain tumor. 1, 2 The mean life span is only 1-2 years after diagnosis, despite aggressive standard treatment, including surgery, radiation and chemotherapy. 3 Radiotherapy confers some survival advantage, but resistance of the tumor cells to the effects of radiation limits the success of treatment. The molecular basis of radioresistance is DNA repair. Ionizing radiation induces a variety of DNA lesions, including single-strand breaks (SSBs) and double-strand breaks (DSBs), which, if not repaired, cause chromosomal abnormalities that prevent normal mitosis and trigger apoptosis, permanent cell cycle arrest or mitotic catastrophe (for a review see Belli et al. 4 ). Critical to cell survival after irradiation is the repair of these lesions, the repair of DSBs in particular. 5 DNA lesions are recognized by DNA repair proteins, which, in concert with cell cycle checkpoints, induce DNA-damage-response pathways. These arrest the cell cycle at G1-, G2-and M phase and may also slow down S phase (for a review see Belli et al. 4 ). Several new approaches to sensitize tumor cells for ionizing radiation recently evolved, resulting not only in clinically accepted new combined treatment modalities on the level of DNA-damage enhancement, but also in targeting tumor cell-specific intracellular signal transduction cascades. 6, 7 With the detailed novel insights on the molecular level, the DNA repair machineries at the center of the cellular response to ionizing radiation now also become an attractive target for radiosensitization.
Two separate repair machineries are of central importance for DSB repair (for a review see Cahill et al.
):
Nonhomologous End Joining (NHEJ) and Homologous Recombination (HR). HR is predominant in the S and G 2 phases of the cell cycle and thus resting normal cells are less prone to mutagenesis, while faster growing tumor cells are more susceptible to DNA-damaging agents in a state of insufficient HR repair. This renders HR to be the more attractive target than NHEJ with regard to a therapeutic window when targeted as part of a combined treatment modality with DNA-damaging agents.
Rad51 is an essential component of the HR repair system and is involved in the formation of the synapsis, the central step of HR. Unwound DNA of the intact copy is paired with the damaged DNA to be used as template for the repair of the damaged DNA strand. Rad51 interacts with BRCA2 in the process of bringing together the two homologous DNA strands. 9 Rad51 and also BRCA2 has been implicated as a mediator of cellular radiosensitivity. 5, [10] [11] [12] Exposure of cells to ionizing radiation induces the formation of Rad51 nuclear foci at DSB sites. 9, [13] [14] [15] [16] In general, decreasing the efficacy of HR sensitizes for ionizing radiation 17 and renders other elements of the HR machinery such as specific HRrelated endo-and exonucleases as interesting targets for radiosensitization. Illegitimate repair of DSBs results in chromosomal instability and rearrangements and eventually in mitotic catastrophy.
The levels of Rad51 have been shown to be higher in tumor cells as compared to normal cells, and high Rad51 levels appear to be consistent with tumor progression and resistance to therapy. 18, 19 Several studies have analyzed the relationship between Rad51 levels and radiation-induced cell death. The transient overexpression of Rad51 resulted in a decrease in radiosensitivity of CHO cells, 19 while the reduction of Rad51 levels using antisense oligonucleotides or a ribozyme enhanced radiosensitivity. [20] [21] [22] The reduction of Rad51 levels using a specific inhibitor (Gleevec) of c-Abl, a tyrosine kinase that plays a role in the regulation of Rad51, also enhances the sensitivity of glioma cells to radiation. 23 One strategy that allows the specific downregulation of any target gene including Rad51 is the degradation of its mRNA by short interfering RNA (siRNA), which is more efficient and specific than the antisense and ribozyme approaches. [24] [25] [26] [27] However, the usefulness of the siRNA approach for therapeutic applications has been limited by the inefficient delivery into cells, at least in vivo. We have recently established a virus-based delivery/expression system for siRNAs using helper virus-free herpes simplex virus-type 1 (HSV-1) amplicon vectors and demonstrated the efficient and specific posttranscriptional inhibition of epidermal growth factor receptor (EGFR). 28 In the present study, we explored the possibility to enhance the effect of radiation therapy by HSV-1 amplicon vector-mediated post-transcriptional silencing of the DNA repair protein Rad51.
Results
HSV-1 amplicon vector-mediated post-transcriptional silencing of Rad51 inhibits the radiation-induced recruitment of Rad51 into the cell nucleus
The goal of this study was to examine the effect of posttranscriptional Rad51 inhibition on the radiosensitivity of human glioma cells. For this, we have designed an HSV-1-based amplicon vector, which expresses a Rad51-specific siRNA from the RNA polymerase III-dependent H1 promoter (pHSVsiRad51; Figure 1 ). We designed the siRNA to target nucleotides 322-340 of the Rad51-coding sequence, because this sequence has been targeted successfully in a previous study. 29 pHSVsiEGFP, which expresses an enhanced green fluorescent protein (EGFP)-specific siRNA, and pHSVsi, which does not express any siRNA, have been described recently 28 and were used as controls in the present study. All amplicons express the EGFP reporter gene from the HSV-1 immediate-early (IE) 4/5 promoter to facilitate vector titration and visualization of the transduced cells. Amplicon vector stocks were prepared by using a helper virus-free packaging protocol. 30, 31 To test the functionality of the vectors, human gli36-luc glioma cells were either mock-infected or infected with pHSVsi, pHSVsiEGFP or pHSVsiRad51 amplicon vectors. Western analysis performed 3 days later showed that Rad51 signals in the pHSVsiRad51-infected cells were reduced by 60-70%, when compared to mock-infected cells or cells infected with the control vectors pHSVsi and pHSVsiEGFP ( Figure 2 ). To further test the functionality of the vectors, we compared the radiation-induced recruitment of Rad51 into nuclear foci between mock-infected cells and cells infected with the HSV-1 amplicon vectors. As shown in Figure 3 , treatment of mock-infected cells with ionizing radiation (3 Gy) resulted in the efficient recruitment of Rad51 into nuclear foci. This recruitment appeared to be efficiently prevented in the pHSVsiRad51-infected cells, as the pHSVsiRad51-infected (green) and irradiated cells contained no or only few Rad51 foci (red) in the cell nucleus Rad51 inhibition and radiosensitivity of human glioma cells O Saydam et al (large vertical arrows), while many nuclear RAD51 foci were present in nontransduced cells in the same culture (small horizontal arrows; Figure 3a , bottom). In the cultures infected with the control vectors pHSVsi or pHSVsiEGFP, Rad51 was efficiently recruited into nuclear foci in both transduced (green, large vertical arrows) or nontransduced (small horizontal arrow) cells following treatment with ionizing radiation. The intensity of the GFP-fluorescence in the pHSVsiEGFP-transduced cells is markedly reduced compared to that of the pHSVsi or pHSVsiRad51-transduced cells, because this vector expresses an EGFP-specific siRNA which can efficiently inhibit the expression of the EGFP reporter gene. 28 The graph in Figure 3b shows the percentage of cells containing nuclear Rad51 foci. In the mock-infected and irradiated cultures, 85.5% of the cells contained nuclear Rad51 foci. Similar numbers were determined for the pHSVsi and pHSVsiEGFP-infected and irradiated cultures (77.5 and 78.8%, respectively). By contrast, the percentage of cells with nuclear Rad51 foci in the pHSVsiRad51-infected and irradiated cultures (25.4%) was similar to that of mock-infected, non-irradiated cultures (22.9%). In summary, these results demonstrate that HSV-1 amplicon vector-encoded siRNA can efficiently reduce the levels of Rad51 and, in addition, prevent the radiation-induced formation of nuclear Rad51 foci, which represent sites of DNA-damage repair, in particular DSB repair.
9,14-16
Vector-mediated post-transcriptional silencing of Rad51 inhibits growth of cultured human glioma cells and induces apoptosis
We examined the effect of post-transcriptional Rad51 inhibition on cell growth and apoptosis in the absence of ionizing radiation. Gli36-luc cells, mock-infected or infected with HSV-1 amplicon vectors (m.o.i. of 5), were counted at days 3 and 6 after infection. There was a significant difference in the cell numbers between pHSVsiRad51-infected cultures and control vector-or mock-infected cultures at day 6 after infection; the reduction was approximately 50% following expression of the Rad51-specific siRNA (Figure 4a ). The inhibition of Rad51 by vector-encoded siRNA induced apoptosis in approximately 22% of the cells, as determined by annexin V staining and fluorescence-activated cell sorting (FACS) analysis at 4 days after infection; the fraction of apoptotic cells in the mock-infected or control vectorinfected cultures was smaller than 5% ( Figure 4b ).
Rad51 inhibition increases the radiosensitivity of glioma cells in culture and in vivo
To examine the effect of Rad51 inhibition on the radiosensitivity of glioma cells, we performed clonogenic survival assays with two different human glioma cell lines, gli36-luc and U87. Similar to the previous experiment (Figure 4b ), infection with pHSVsiRad51 vector in the absence of irradiation resulted in a significant reduction of cell growth; colony formation was reduced by approximately 50% relative to mock-infected or control vector-infected gli36-luc cells (Figure 5a ) or U87 cells ( Figure 5b ). Nevertheless, there was a clear effect of Rad51 inhibition on the radiosensitivity of these cells. Irradiation of mock-infected gli36-luc or U87 cells reduced the numbers of colonies by 45 and 27%, respectively. Almost identical reductions in colony numbers from before and after irradiation were obtained when cells were infected with the control vectors pHSVsiEGFP (53% in gli36-luc; 30% in U87) and pHSVsi (51% in gli36-luc; 29% in U87). By contrast, irradiation of pHSVsiRad51-infected cultures resulted in significantly higher reductions in the numbers of colonies, 78% in gli36-luc cells and 75% in U87 cells.
Next, we examined whether HSV-1 amplicon vectormediated post-transcriptional inhibition of Rad51 could enhance the effect of radiation therapy in a mouse tumor model. For this, 3.5 Â 10 6 gli36-luc cells were subcutaneously inoculated into the right flanks of athymic mice. When the tumors reached a volume of approximately 150 mm 3 , the tumors were injected with a single dose of HSV-1 amplicon vectors (1 Â 10 7 transducing units (t.u.) in 30 ml) or phosphate-buffered saline (PBS). Two days later, three of the six animals in each group were treated once with ionizing radiation (6 Gy). Three days after irradiation, the tumor volumes were determined and compared between the experimental groups. As shown in Figure 6 , the control vector pHSVsiEGFP did not enhance the effect of irradiation, when compared to the PBS-treated and irradiated tumors. However, the effect 
Discussion
Standard therapy for glioblastoma multiforme and other brain tumors consists of surgical resection followed by radiation in combination with chemotherapy. However, even at high radiation doses, the tumors recur in most patients and are (or become) resistant to further treatment. Therefore, the development of combination ). Ionizing radiation induces a variety of DNA lesions, including SSBs and DSBs. 32 Critical to cell survival after irradiation is the repair of these lesions, the repair of DSB in particular. 33, 34 Thus, inhibition of specific DNA repair processes as part of a combined treatment modality has the potential to develop into a selective tumor-targeting strategy and has gained immense interest in basic and applied radiobiology in recent years. This has been successfully demonstrated by targeting both NHEJ and HR. Noteworthy, HR may be the more interesting target for achieving tumor specificity and increasing a therapeutic window, because of its increased activity in S and G2 phases of the cell cycle. This holds true especially in neuro-oncology, because in resting cells, such as the post-mitotic neuronal cells, as opposed to the tumor cells, DNA repair is attenuated. 35, 36 Due to the lack of small molecules, which directly inhibit HR-activity, reduction of Rad51 levels by genetic approaches to downregulate HR is highly promising. Likewise other genetic approaches using antisensetechnology against other key elements of HR sensitizes for ionizing radiation. Here, we demonstrate that the HSV-1 amplicon vector-mediated post-transcriptional inhibition of Rad51, which is an essential component of the homologous DNA-repair pathway, 5,10-12 efficiently suppressed the radiation-induced recruitment of Rad51 into nuclear foci and significantly enhanced the radiosensitivity of human glioma cells. The combination of Rad51 inhibition, mediated by intratumoral injection of HSV-1 amplicon vectors that express Rad51-specific siRNA, and irradiation resulted in the regression of subcutaneous tumors in mice. For the Rad51-specific siRNA, we have chosen a sequence homologous to nucleotides 322-340 of the Rad51-coding sequence. An siRNA of identical sequence has recently been demonstrated to efficiently inhibit Rad51 expression in a different study. 29 Those investigators demonstrated that or STI571 (Gleevec), which is a specific inhibitor of the tyrosine kinase c-Abl that is involved in the regulation of Rad51, 23 enhanced the radiosensitivity of tumor cells, providing further evidence for the role of Rad51 as a mediator of cellular radioresistance.
At the same time, it will be important to delineate genetic background dependence for successful Rad51-based radiosensitization. Furthermore, HR itself is also often deregulated in cancer cells due to genetic mutations of some of its elements. 37 On the other hand, this also opens new possibilities as recently demonstrated by targeting specific BRCA2-mutated cancer types. 38, 39 Our approach using HSV-1 amplicon vectors for the delivery/expression of siRNAs has several advantages over these previous strategies: (i) HSV-1-based vectors are well suited to treat diseases affecting the central nervous system, including tumors, and have entered already clinical applications. 40, 41 (ii) The replicationdefective, 'gutless' HSV-1 amplicon vectors can target cells and tissues not accessible by transfection. Moreover, amplicon vectors have a transgene capacity of 150 kbp, which allows to include additional genes that have therapeutic, regulatory and/or imaging functions. The inclusion of the EGFP reporter gene in our vectors facilitated the titration of the vector stocks and the visualization of cell transduction over time. (iii) Depending on the size of the transgenes, numerous copies are packaged into a single amplicon vector particle (approximately 22 copies per pHSVsiRad51 vector particle), thereby supporting high levels of siRNA expression and efficient inhibition of the target (60-70%; Figure 2 ). (iv) As no virus proteins are encoded, amplicons are nearly nontoxic when packaged using a helper virus-free system and, per se, do not induce nonspecific DNAdamage responses. 30, 31, [42] [43] [44] [45] (v) In a recent study, we have demonstrated the effectiveness of HSV-1 amplicon vectors for the post-transcriptional inhibition of EGFR, another target protein relevant in neuro-oncology. The inhibition of EGFR resulted in a pronounced growth inhibition of human glioma cells in culture and in athymic mice in vivo.
28
Following delivery of synthetic Rad51-specific siRNA by HVJ envelope vectors, Rad51 protein completely disappeared for 4 days after transfer in HeLa cells using an m.o.i of 10 4 HVJ particles per cell. 29 We achieved a strong (60-70% reduced signal in western blot analysis), albeit not complete, reduction of Rad51 protein levels in our study in gli36-luc glioma cells with a 2000-fold lower m.o.i. (5 t.u./per cell; Figure 2) .
The post-transcriptional inhibition of Rad51 induced considerable apoptosis of glioma cells also in the absence of irradiation (Figures 4b and 5) . This was not unexpected, as a previous study has demonstrated that the conditional targeting of Rad51 in chicken DT40 cells resulted in an arrest of the cell cycle at the G2/M phase followed by cell death. 11 Moreover, Rad51 knockout mice have been shown to be mortal in early embryogenesis. 46, 47 These findings indicate that Rad51 is essential for the proliferation and survival of eukaryotic cells. While the inhibition of Rad51 may not cause adverse effects to post-mitotic neurons in which DNA repair is attenuated, 35, 36 adverse effects to normal proliferating cells should be minimized or eliminated, for example, by tumor-selective targeting of the vectors or tumorselective expression of the siRNA or both. Tumor selective targeting of the vectors may be achieved by incorporating antibodies to mutant EGFR into the vector particle. The problem of limited diffusion of HSV-1 particles in solid tumors may be overcome by multiple injections or by using replication-conditional recombinant HSV-1 vectors.
In conclusion, this study provides proof of principle for the selective post-transcriptional inhibition of Rad51 by HSV-1 amplicon vector-mediated siRNA delivery/ expression, as a strategy to enhance the radiationinduced death of tumor cells.
Materials and methods

Cells
Human gli36-luc glioma cells 28 were grown in Dulbecco's minimal essential medium (DMEM) supplemented with 
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10% fetal bovine serum (FBS), 500 mg/ml G418, 100 U/ml penicillin, and 100 mg/ml streptomycin at 371C in a 5% CO 2 atmosphere. Human glioma U87 cells (American Type Culture Collection) were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin at 371C in a 5% CO 2 atmosphere.
HSV-1 amplicon vectors
pHSVsi is a basic HSV-1 amplicon plasmid that contains an HSV-1 origin of DNA replication (ori), the HSV-1 DNA packaging/cleavage signal (pac), and the HSV-1 IE 4/5 promoter to express the EGFP reporter gene (Figure 1) . A second transcription unit consists of the RNA polymerase III-dependent H1 promoter and welldefined start and termination signals for the synthesis of siRNA. 28 pHSVsiEGFP is a derivative of pHSVsi, which expresses an EGFP-specific siRNA (Figure 1 ; Saydam et al. 28 ). For targeting the Rad51 mRNA, 64-mer sense and antisense oligonucleotides containing the targeting sequence (GAGCTTGACAAACTACTTC) were synthesized (Microsynth, Balgach, Switzerland), self-annealed and inserted into pHSVsi between the BglII and the HindIII sites (Figure 1 ). Amplicon DNA was packaged into HSV-1 particles as described previously, 31 and the titers of vector stocks were determined by counting the number of green cells at 24 h after infection (t.u./ml).
Western blot analysis
Western blot analysis was performed essentially as described in Saydam et al. 28 Briefly, gli36-luc cells were seeded into 6-cm-diameter tissue culture plates (1.2 Â 10 6 cells/plate) and, the following day, either mock-infected or infected with HSV-1 amplicon vectors (m.o.i. of 5). After 3 days, cells were harvested, and total protein was separated on a SDS-12% polyacrylamide gel and blotted onto nitrocellulose. The membrane was blocked with 5% nonfat dry milk in PBS-T (PBS containing 0.05% Tween 20) for 2 h at 371C, then rinsed once with PBS-T and washed twice for 15 min and twice for 5 min at room temperature with TBS-T (50 mM Tris-HCl (pH 7.9), 150 mM NaCl, 0.01% Tween 20) . The primary antibodies were diluted 1:100 (anti-Rad51 antibody; Abcam, Cambridge, UK) or 1:1000 (anti-b-tubulin antibody; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in TBS-T containing 2% nonfat dry milk and applied to the membrane. After incubation overnight at 41C, the membrane was washed twice for 15 min and twice for 5 min at room temperature with TBS-T and then incubated for 1 h at room temperature with a horseradish-conjugated rabbit anti-mouse secondary antibody (Santa Cruz Biotechnology) diluted 1:2500 in TBS-T containing 2% nonfat dry milk. Bands were visualized using the electric control loading system according to instructions provided by the supplier (Amersham, Buckinghamshire, UK). After scanning and analyzing the bands on the western blot by using Image Quant 5.2 (Molecular Dynamics Sunnyvale, CA, USA), the relative signals of the Rad51 bands were calculated by normalization with the b-tubulin signals.
Indirect immunofluorescence
Gli36-luc cells cultured on coverslips were infected with HSV-1 amplicon vectors at an m.o.i. of 5 and 3 days later, irradiated (3 Gy). After irradiation (6 h), cells were fixed for 15 min at 41C with 4% paraformaldehyde in PBS and subsequently permeabilized for 20 min at room temperature with 0.3% Triton X-100 in PBS. After blocking for 30 min at room temperature with 2% BSA in PBS, the cells were incubated overnight at 41C with monoclonal mouse anti-Rad51 antibody (Abcam, Cambridge, UK; 1:100). The slides were washed three times with PBS and incubated for 1 h at room temperature with Cy3-conjugated rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA; 1:200). After washing three times with PBS, coverslips were mounted using Vectashield medium (Vector Laboratories, Burlingame, CA, USA) and images were captured using an Olympus IX81 fluorescence microscope.
Growth rate
Gli36-luc cells were seeded in six-well plates (5 Â 10 3 cells/well) and infected on the next day with HSV-1 amplicon vectors (m.o.i. of 5; in triplicate). Cells were counted at 3 and 6 days after infection using a hemocytometer.
Apoptosis assay
Apoptotic cell death was determined using the Annexin V-Cy3 Apoptosis Detection Kit (Abcam, Cambridge, UK) according to the manufacturer's instruction. Briefly, gli36-luc cells were seeded into 12-well plates (1 Â 10 5 cells/ well) and infected on the next day with HSV-1 amplicon vectors (m.o.i. of 5). After 4 days, the cells were harvested, washed with PBS, and then suspended in annexin V binding buffer. The cells were stained for 15 min at room temperature in the dark and analyzed on a FACSAria flow cytometer using BD-FACSDiVa software (BectonDickinson, Basel, Switzerland).
Clonogenic survival assay
Clonogenic survival assays were performed to determine the survival fraction. Gli36-luc and U87 cells (in triplicate) were transduced with HSV-1 amplicon vectors (m.o.i. of 5). After 24 h, the cells were trypsinized and plated onto 100-mm-diameter cell culture dishes (10 4 cells per dish). At 24 h after plating, the cells were irradiated with 0, 3 or 6 Gy. After 10-14 days of incubation, the colonies were stained with MayGrü nwald (Sigma, Buchs, Switzerland) and counted. Only colonies with a minimum of 50 viable cells were counted.
Animal studies
All animal procedures were approved and performed according to guidelines issued by the Committee of Animal Care of the Kanton Zurich. Female 4-6-week-old (20-24 g) athymic nude mice (nu/nu; Charles River Laboratories, Sulzfeld, Germany) were used to investigate the effect of post-transcriptional inhibition of Rad51 expression on radiosensitivity of glioma xenografts. The cells (3.5 Â 10 6 gli36-luc cells in 100 ml PBS) were subcutaneously inoculated into the right flanks of the mice. The tumor volume was determined from caliper measurements using the formula: volume ¼ length Â width Â height/2. When tumors reached a volume of approximately 150 mm 3 , the animals were randomly divided into three groups of six animals each; the tumor volumes at this time point was set as the value of 100%. The animals of group 1 were then injected intratumorally with 30 ml of PBS and those of groups 2 and 3 were Rad51 inhibition and radiosensitivity of human glioma cells O Saydam et al injected intratumorally with 1 Â 10 7 t.u. of the pHSVsiEGFP control amplicon vector (in 30 ml PBS) or the Rad51-specific amplicon vector (pHSVsiRad51; in 30 ml), respectively. Two days after vector injection, three of the animals in each group were treated with ionizing radiation (6 Gy; 0.7 Gy/min; Pantak Therapax 3300 kV X-ray unit) using a customized shielding device to allow strictly locoregional radiotherapy. Three days later, the tumor volumes were determined in all animals.
Statistical analysis
Values are expressed as means7s.d.; P-values were calculated by using the Student's t-test, and values of Po0.05 were regarded as significant.
